18F-AlF-FAPi-04 PET/CT Imaging in Patients With Solid Tumor

Status Recruiting

Clinical Trial Summary

To evaluate the potential usefulness of 18F-AlF-FAPi-04 PET/CT for the diagnosis of primary and metastatic lesions in solid cancer.

Clinical Trial Description

This is a prospective, single-center, two arms, open label, non-randomized study to evaluate the ability of 18F-AlF-FAPi-04 to detect FAP expressing cells in patients with solid tumor, evaluate its biological distribution characteristics, impact on clinical treatment plans, and evaluate imaging differences between different probes. Taking histopathology and imaging follow-up as gold standard, the sensitivity, specificity, and accuracy of 18F-AlF-FAPi-04 PET/CT will be calculated. ;

Study Design

Related Conditions & MeSH terms

Tumor, Solid

Clinical Trial Details

NCT number	NCT06126705
Study type	Interventional
Source	Af?liated Hospital of North Sichuan Medical College
Contact	Huang xiaohong, MM
Phone	+86 158 8266 2030
Email	huangxiaohong2@126.com
Status	Recruiting
Phase	Early Phase 1
Start date	July 18, 2023
Completion date	July 2024

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05094804` - A Study of OR2805, a Monoclonal Antibody Targeting CD163, Alone and in Combination With Anticancer Agents	Phase 1/Phase 2
Recruiting	`NCT05637034` - 68Ga-DOTA-F2 PET/CT in Patients With Various Types of Cancer	N/A
Terminated	`NCT04095091` - Real-time Tumor Localization and Guidance for Radiotherapy Using Ultrasound (US) and Magnetic Resonance (MR)
Recruiting	`NCT05378425` - A Study of NTX-1088, a Monoclonal Antibody Targeting the Poliovirus Receptor (PVR, CD155), as Monotherapy and Combined With Pembrolizumab	Phase 1
Not yet recruiting	`NCT04723810` - TumorGlow Intraoperative Molecular Imaging (IMI)	Phase 1/Phase 2
Recruiting	`NCT06116032` - Immune Profiling for Cancer Immunotherapy Response
Recruiting	`NCT06090266` - A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents	Phase 1/Phase 2
Recruiting	`NCT04416165` - Comparison of FDG and FAPI in Patients With Various Types of Cancer	N/A
Recruiting	`NCT05620134` - Study of JK08 in Patients With Unresectable Locally Advanced or Metastatic Cancer	Phase 1/Phase 2
Recruiting	`NCT04750772` - Positron Nuclide Labeled DOTA-FAPI PET Study in Colocrectal Cancer	N/A
Recruiting	`NCT06022029` - A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.	Phase 1
Terminated	`NCT01358331` - A Study of the Safety, Tolerability, and Efficacy of MK-8353 in Participants With Advanced Solid Tumors (MK-8353-001)	Phase 1
Recruiting	`NCT06175221` - Autologous TLPO Vaccine Basket	Phase 2
Recruiting	`NCT05661461` - Dose-escalation Study to Assess Safety and Pharmacokinetics of Nab-Sirolimus in Patients With Locally Advanced or Metastatic Solid Tumors and Moderate Liver Impairment	Phase 1
Active, not recruiting	`NCT04196530` - BDB001-102: Open Label Dose Escalation of BDB001 in Combination w Atezolizumab	Phase 1
Not yet recruiting	`NCT03731390` - GR1405 Injection in Patients With Advanced Solid Tumor or Lymphoma	Phase 1
Active, not recruiting	`NCT03491631` - Phase I Study of SHR9146 + SHR-1210 +/- Apatinib in Patients With Advanced Solid Tumors	Phase 1
Recruiting	`NCT06193902` - LEU01101: Safety and Preliminary Efficacy of LEU011 in Solid Tumours.	Phase 1/Phase 2
Active, not recruiting	`NCT04528836` - First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors	Phase 1
Recruiting	`NCT05221320` - Trial of Ulixertinib in Combination With Hydroxychloroquine in Patients With Advanced Gastrointestinal (GI) Malignancies	Phase 2